Kintara Therapeutics, Inc. Stock Price, News & Analysis

Kintara Therapeutics (KTRA) announced the closing of a registered direct offering of 16,226,416 common stock shares and warrants, raising approximately $8.6 million at a price of $0.53 per share. The warrants, with an exercise price of $0.41, are immediately exercisable for five years. Funds from this offering are intended for clinical studies and general corporate purposes, including potential acquisitions. Kintara is advancing therapeutics for glioblastoma and cutaneous metastatic breast cancer, emphasizing its commitment to addressing unmet medical needs.

Kintara Therapeutics, Inc. (Nasdaq: KTRA) announced a registered direct offering, selling 16,226,416 shares and warrants at $0.53 each, aiming for gross proceeds of approximately $8.6 million. The warrants, with an exercise price of $0.41, will expire in five years. Proceeds will fund clinical studies, working capital, and potential acquisitions. The offering, underpinned by a shelf registration, is expected to close on April 14, 2022. Kintara is focused on developing innovative cancer therapies, particularly VAL-083 for glioblastoma and REM-001 for Cutaneous Metastatic Breast Cancer.

Kintara Therapeutics, Inc. (NASDAQ: KTRA) presented significant data at the 2022 American Association for Cancer Research (AACR) Annual Meeting on April 11, 2022. The focus was on VAL-083, a treatment for glioblastoma multiforme (GBM), showing enhanced drug concentrations in brain tumors compared to plasma. The study indicated that VAL-083 may cross the blood-brain barrier (BBB) via passive diffusion rather than glucose transporters, suggesting greater dosing precision. Kintara continues to develop VAL-083 and REM-001 to address unmet medical needs in cancer therapies.

Kintara Therapeutics (Nasdaq: KTRA) will participate in the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. President and CEO Robert Hoffman will deliver a corporate overview available on March 28 at 9:00 a.m. ET. The company focuses on developing innovative cancer therapies with two late-stage candidates: VAL-083 for Glioblastoma Multiforme and REM-001 for Cutaneous Metastatic Breast Cancer. Kintara aims to address unmet medical needs through these therapeutics.

Kintara Therapeutics (Nasdaq: KTRA) announced it will present data at the 2022 AACR Annual Meeting in New Orleans from April 8-13, 2022. The presentation focuses on VAL-083, a first-in-class chemotherapeutic for Glioblastoma Multiforme (GBM), highlighting its mechanism of crossing the blood-brain barrier. Kintara is also advancing REM-001, a therapy for Cutaneous Metastatic Breast Cancer (CMBC), which has shown an 80% complete response rate in prior trials. The company is committed to developing effective cancer therapies for patients with unmet needs.

Kintara Therapeutics (KTRA) reported financial results for the fiscal second quarter ending December 31, 2021, showing a net loss of $5.9 million, or $0.12 per share, compared to a loss of $5.4 million, or $0.22 per share, for the same period in 2020. Cash and cash equivalents stood at approximately $14 million. The company highlighted key developments, including the award of a U.S. patent for VAL-083 for treating brain tumors and successful patient enrollment in the GBM AGILE study, with over 1,000 patients screened. Management changes were also announced, with Robert E. Hoffman taking over as CEO.

Kintara Therapeutics (Nasdaq: KTRA), a biopharmaceutical company focused on cancer therapies, announced its CEO, Robert E. Hoffman, will present at the BIO CEO & Investor Conference on February 15, 2022, at 2:00 p.m. EST in New York City. Kintara is advancing two late-stage therapies: VAL-083 for Glioblastoma Multiforme and REM-001 for Cutaneous Metastatic Breast Cancer, both addressing significant unmet needs. VAL-083 has shown activity against various cancers, while REM-001 has demonstrated an 80% complete response in previous trials. More details are available on their website.

Kintara Therapeutics has received U.S. Patent No. 11,234,955, allowing for claims on a method to treat brain tumors, including glioblastoma, that are resistant to current therapies due to the MGMT enzyme. VAL-083, the patented compound, demonstrates anti-neoplastic activity against malignant brain tumor cells expressing MGMT, offering treatment options for both newly diagnosed and recurrent patients. The patent also covers VAL-083's efficacy against medulloblastoma and tumor stem cells, which may lead to improved patient outcomes.

Kintara Therapeutics (Nasdaq: KTRA) announced a multiyear research grant from the Luxembourg National Research Fund and Cancer Foundation Luxembourg to support Dr. Anna Golebiewska's research on VAL-083's mechanism of action in treating glioblastoma (GBM). The project aims to understand treatment resistance and improve patient stratification. VAL-083 is being advanced in the GBM AGILE study. This grant underscores Kintara's commitment to developing innovative cancer therapies, particularly for patients with limited treatment options.